Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Italian study tests smarter lung cancer screening: fewer scans, same Life-Saving power?

NCT ID NCT05766046

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Italian study is testing whether heavy smokers can be screened for lung cancer just as effectively with a CT scan every two years instead of every year, and whether a simple blood test can help catch cancers early. Over 7,300 current or former heavy smokers are taking part across 18 centers. The goal is to make lung cancer screening more practical and less burdensome, while also offering smoking cessation support.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low-dose CT scan and blood test for microRNA biomarkers
What this could lead to
If successful, this could make lung cancer screening more efficient by using less frequent CT scans and blood tests, catching cancer early while reducing radiation exposure and costs.
What could go wrong
This is an observational screening study, not a treatment trial. The blood test may not prove reliable enough to replace CT scans, and results may not apply to non-Italian populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 7,324 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Active smoker (≥ 30 packs/year) * Former heavy smoker for ≤ 15 years (≥ 30 packs/year) * Absence of tumors for at least 5 years * Signature of informed consent for studio enrollment and processing of personal data Exclusion Criteria: * Severe chronic disease (e.g. severe respiratory and/or renal and/or hepatic and/or cardiac failure) * Severe psychiatric problems * Abuse of alcohol or other substances (including previous)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chiara Bovolenta

    Milan, MI, 20133, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.